J.W. Cole Advisors Inc. Has $2.22 Million Stake in Medtronic PLC $MDT

J.W. Cole Advisors Inc. raised its holdings in Medtronic PLC (NYSE:MDT) by 36.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,441 shares of the medical technology company’s stock after purchasing an additional 6,824 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Medtronic were worth $2,218,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in MDT. Farmers National Bank raised its holdings in shares of Medtronic by 1.5% in the second quarter. Farmers National Bank now owns 46,281 shares of the medical technology company’s stock valued at $4,034,000 after buying an additional 673 shares during the last quarter. Manchester Capital Management LLC increased its position in Medtronic by 3.2% in the 2nd quarter. Manchester Capital Management LLC now owns 5,824 shares of the medical technology company’s stock valued at $508,000 after acquiring an additional 180 shares in the last quarter. FourThought Financial Partners LLC raised its stake in shares of Medtronic by 2.4% in the second quarter. FourThought Financial Partners LLC now owns 179,751 shares of the medical technology company’s stock worth $15,669,000 after acquiring an additional 4,248 shares during the last quarter. SlateStone Wealth LLC raised its stake in shares of Medtronic by 6.2% in the second quarter. SlateStone Wealth LLC now owns 59,284 shares of the medical technology company’s stock worth $5,168,000 after acquiring an additional 3,442 shares during the last quarter. Finally, Laurel Wealth Advisors LLC lifted its position in shares of Medtronic by 8,779.8% during the second quarter. Laurel Wealth Advisors LLC now owns 1,069,664 shares of the medical technology company’s stock worth $93,243,000 after purchasing an additional 1,057,618 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Down 0.2%

Shares of Medtronic stock opened at $105.13 on Friday. The business has a fifty day simple moving average of $95.87 and a 200 day simple moving average of $91.48. The stock has a market cap of $134.85 billion, a PE ratio of 28.96, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. Medtronic PLC has a 12 month low of $79.29 and a 12 month high of $106.33.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The company’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts predict that Medtronic PLC will post 5.46 EPS for the current year.

Analyst Ratings Changes

MDT has been the subject of a number of research reports. Truist Financial raised their price target on shares of Medtronic from $103.00 to $110.00 and gave the company a “hold” rating in a report on Thursday, November 20th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research note on Wednesday, October 8th. JPMorgan Chase & Co. boosted their target price on Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research report on Thursday, November 13th. Wells Fargo & Company raised their price target on Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Medtronic in a research report on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Medtronic currently has an average rating of “Moderate Buy” and a consensus target price of $109.72.

Insiders Place Their Bets

In related news, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares of the company’s stock, valued at $3,261,621.70. This trade represents a 19.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.26% of the stock is owned by insiders.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.